United Therapeutics (UTHR) CEO Rothblatt Sells $5.6M of Stock
Key Points
- Martine A Rothblatt, Chairperson and CEO of United Therapeutics, sold 9,500 shares at a price of $588.64 each, totaling about $5.6 million.
- After this sale, Rothblatt owns 324,443 shares, which is a decrease of about 2.84% from her previous holdings.
- United Therapeutics has a recent stock price of $591.20, which is below its 52-week high of $609.35 but above its 200-day moving average.
Since the trade, $UTHR is down 0.3% to date (from the $592.84 close on Oct 26, 2026).
Get United Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $UTHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated United Therapeutics Corporation alert may contain errors. Disclosures
Martine A Rothblatt, Chairperson and CEO of United Therapeutics Corporation (UTHR), sold 9,500 shares on October 26, 2026, for approximately $5,592,094. This transaction was reported through a Form 4 filing with the SEC. Rothblatt's planned sale comes after several similar transactions earlier in the month, where she sold shares on October 20, 21, 22, and 23.
In this latest sale, Rothblatt sold the shares at a price of $588.64 each. After this transaction, she now holds 324,443 shares of the company, cutting her stake by about 2.84%. The recent stock price of UTHR is $591.20, which is about 0.3% below the closing price of $592.84 on the day of the sale.
UTHR
United Therapeutics Corporation
Other Institutional Activity in United Therapeutics
Several other institutional investors have also adjusted their positions in United Therapeutics. Avoro Capital Advisors LLC increased its holdings by 147,804 shares, bringing its total to 2,777,777 shares worth about $1.64 billion. In contrast, Renaissance Technologies, LLC reduced its stake by 78,271 shares, ending up with 1,708,739 shares valued at approximately $1.01 billion. Jupiter Topco LLC grew its position significantly, adding 415,564 shares for a total of 831,129 shares worth around $491.4 million.
United Therapeutics Corporation Stock Down 0.3%
As of October 27, 2026, United Therapeutics trades at $591.20. This price is below its 52-week high of $609.35 but remains above both its 50-day and 200-day moving averages by about 13.4% and 11.7%, respectively. The stock's performance indicates a strong position in the market, despite being slightly below its recent peak.
Recent Earnings
United Therapeutics reported trailing twelve-month revenue of approximately $3.15 billion, with an earnings per share (EPS) of $27.92. The company has a net margin of 41.6%, suggesting it maintains a healthy profitability level. The next earnings report is scheduled for November 4, 2026.
Insider Buying and Selling at United Therapeutics Corporation
In addition to the recent sale, Martine A Rothblatt has been active in selling shares throughout October 2026. She sold 9,500 shares on October 20 for about $5.3 million, on October 21 for approximately $5.3 million, on October 22 for about $5.5 million, and again on October 23 for roughly $5.5 million. These planned sales reflect a strategic approach to her holdings in the company.
Analysts Set New Price Targets
On October 1, 2026, BTIG upgraded United Therapeutics to a Buy rating with a target price of $728.00. Morgan Stanley maintained an Equal-Weight rating with a target of $566.00 on October 7, while RBC Capital also kept an Outperform rating with a target of $708.00 on October 8. The consensus among analysts suggests a positive outlook with a mean target price of $672.00.
About United Therapeutics
United Therapeutics Corporation focuses on developing and commercializing innovative products to meet the medical needs of patients with chronic and life-threatening diseases. Headquartered in Silver Spring, Maryland, the company operates within the healthcare sector, specifically in the drug manufacturing industry.
Bottom Line
Investors should keep an eye on United Therapeutics as it approaches its next earnings report on November 4, 2026. Additionally, further insider trades by Rothblatt might provide insight into her confidence in the company's future performance.
Related Filing Alerts
Source: Martine A Rothblatt's Form 4 filing on $UTHR (Oct 26, 2026). Written by software, not financial advice. How we make alerts